Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 15/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986276 | 0.91 | POLB (0.47) | MKNK1KMT2AL3MBTL1PKM | |
| SCHEMBL4989313 | 0.90 | MKNK1 (0.51) | MKNK1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4991405 | 0.89 | MKNK1 (0.45) | MKNK1ALDH1A1 | |
| SCHEMBL4988082 | 0.87 | KMT2A (0.55) | MKNK1KMT2AL3MBTL1PKMPKLR | |
| SCHEMBL4988239 | 0.87 | MKNK1 (0.42) | MKNK1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4989331 | 0.84 | MKNK1 (0.43) | MKNK1KMT2AL3MBTL1PKMALDH1A1 | |
| SCHEMBL4983025 | 0.83 | MEN1 (0.53) | MKNK1KMT2APKMALDH1A1MAPT | |
| SCHEMBL4986106 | 0.81 | PKM (0.50) | MKNK1KMT2AL3MBTL1PKMPKLR | |
| SCHEMBL4986062 | 0.78 | ALDH1A1 (0.52) | KMT2AL3MBTL1PKMALDH1A1MAPT | |
| SCHEMBL4992568 | 0.78 | MEN1 (0.46) | MKNK1KMT2AL3MBTL1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | MKNK1 1672/4885KMT2A 4614/4885L3MBTL1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.